<DOC>
	<DOCNO>NCT01362582</DOCNO>
	<brief_summary>A randomised multicentre clinical phase IIIb trial patient suffer pancreatic adenocarcinoma receive define second high line chemotherapy additionally parenteral nutrition ( study arm A ) best supportive nutritional care ( study arm B ) .</brief_summary>
	<brief_title>Comparing Parenteral Nutrition v Best Supportive Nutritional Care Patients With Pancreatic Cancer</brief_title>
	<detailed_description>Pancreatic cancer extremely aggressive malignancy characterize extensive invasion , early metastasis , mark cachexia . Subjects afflict variety disconcerting symptom , include profound cachexia deterioration performance status , even tumour burden low . Therefore , one important therapeutic target improvement quality life . Supplementation parenteral nutrition improve Quality Life subject advance cancer cachexia . The European Society Parenteral Enteral Nutrition recommend PN malnourish subject reflect situation cancer cachexia patient At present , 2nd-line therapy ( high ) recommend pancreatic adenocarcinoma , often ask . Within clinical trial , evaluate parenteral nutrition combination chemotherapy subject advance pancreatic adenocarcinoma impact quality life ?</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Written inform consent Histological confirm advanced pancreatic adenocarcinoma At least one previous chemotherapy ( gemcitabinebased ) ≥ 18 year old Body weight ≥ 50 ≤ 95 kg BMI ≥ 19 Negative pregnancy test ( female childbearing potential ) Willingness perform doublebarrier contraception study Expected life expectancy &gt; 3 month Major surgery &lt; 4 week prior enrollment Weight loss &gt; 2 % within last seven day caloric intake ≤ 500 kcal expect within next five day PINIIndex &gt; 10 Pregnancy breastfeed &gt; 4 week parenteral nutrition within last 6 month Parenteral nutrition &lt; 4 week prior enrollment Vulnerable population ( e.g . subject incapable give consent personally ) Subject selection conflict warning , precaution contraindication state investigational product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>progression chemotherapy</keyword>
	<keyword>parenteral nutrition</keyword>
	<keyword>pancreatic adenocarcinoma</keyword>
	<keyword>chemotherapy</keyword>
</DOC>